Global Non-Small Cell Lung Cancer Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastina Tumours, Mesothelioma and Chest Wall Tumours), Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multi-kinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others) – Industry Trends and Forecast to 2030.
Non-Small Cell Lung Cancer Market Analysis and Size
According to data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH), approximately 85% of lung cancer cases in the United States are NSCLC. Squamous cell carcinoma accounted for 30% of the cases, adenocarcinoma accounted for 40%, and large-cell carcinoma accounted for 15%. Furthermore, all other country-based registries reported nearly the same percentage of NSCLC and its major subtypes.
Data Bridge Market Research analyses that the non-small cell lung cancer market which is USD 26948.36 million in 2022, is expected to reach USD 76334.72 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Non-Small Cell Lung Cancer Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastina Tumours, Mesothelioma and Chest Wall Tumours), Type (Adenocarcinomas, Squamous Cell Carcinoma, Large Cell Carcinomas, and Others), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multi-kinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Diagnosis (CT Scan, X-Rays, Sputum Cytology, Bronchoscopy, Laboratory Tests, Thoracoscopy, and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), CLOVIS ONCOLOGY (U.S.), Johnson & Johnson Private Limited (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Non-small cell lung carcinoma (NSCLC), also known as non-small cell lung cancer, is the most common type of lung cancer. The term "non-small cell" refers to the appearance of cancer cells under a microscope. Small cell lung cancer is named after the size of the cells (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC is less likely to spread than SCLC and has a higher survival rate. The majority of people with early-stage NSCLC survive at least 5 years, but the survival rate is much lower if the cancer has spread to other tissues at the time of diagnosis.
Non-Small Cell Lung Cancer Market Dynamics
Drivers
- Increase in Cancer Cases
The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2016, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year. Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for 1.59 million deaths in 2012. This boosts market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Development of Diversified Treatments
Patients are given treatments such as chemotherapy and radiation therapy to treat early-stage small cell lung cancer. These provide significant advantages to patients. Radiation therapy, for example, is given to patients to shrink tumour cells as well as relieve symptoms such as coughing, difficulty swallowing, bleeding, and shortness of breath. Three-dimensional conformal radiation therapy (3D-CRT) and intensity modulated radiation therapy (IMRT) are two types of radiation techniques commonly used in treatment.
- Rising Healthcare Awareness
The incidence of small cell lung cancer (SCLC) is becoming more widely known among patients and healthcare providers. Patients and doctors are now taking a more active role in learning about the therapies available for the treatment of these severe diseases. This is one of the most important market drivers. This expands the market's opportunities.
Restraints/Challenges
- Lack of Skilled Professionals
Lack of trained professionals who are unaware of treatment methods for this disease may limit the growth of the global non-small cell lung cancer market during the forecast period.
This non-small cell lung cancer market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-small cell lung cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on the Non-Small Cell Lung Cancer Market
Since December 2019, the COVID-19 pandemic has had little impact on the global non-small lung cancer market. In top economies such as China, the United States, and the European Union, key industry therapies for non-small cell lung cancer include chemotherapy, radiation therapy, surgery, and targeted therapy. The COVID-19 pandemic in these major economies has caused treatment delays around the world. Furthermore, frequent hospital visits may significantly increase the risk of infection, prompting many patients to postpone treatment. The 30-day mortality rate in patients with newly diagnosed NSCLC increased significantly during the global pandemic, from 25% before COVID-19 to 49% during COVID-19. However, the market will experience a "W" shape recovery in the near future due to an increase in the number of patients who experienced treatment delays in major economies. Due to the majority of economies being affected by the second wave, the market will show a decline in share twice.
Recent Developments
- In 2019, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation based in the United States, received European Commission (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
- In 2021, Daiichi Sankyo received FDA approval for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.
Global Non-Small Cell Lung Cancer Market Scope
The non-small cell lung cancer market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Cancer Type
- Non-Small Cell Lung Cancer
- Metastatic Lung Cancer
- Pulmonary Neuroendocrine Tumours
- Mediastina Tumours
- Mesothelioma
- Chest Wall Tumours
Type
- Adenocarcinomas
- Squamous Cell Carcinoma
- Large Cell Carcinomas
- Others
Molecule Type
- Small Molecules
- Biologics
Drug Class
- Alkylating Agents
- Antimetabolites
- EGFR Inhibitors
- Mitotic Inhibitors
- Multi-kinase Inhibitors
- Others
Treatment Type
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Immunotherapy
- Others
Diagnosis
- CT Scan
- X-Rays
- Sputum Cytology
- Bronchoscopy
- Laboratory Tests
- Thoracoscopy
- Others
Therapy Type
- Single Drug Therapy
- Combination Therapy
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online
- Others
Non-Small Cell Lung Cancer Market Regional Analysis/Insights
The non-small cell lung cancer market is analyzed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.
The countries covered in the non-small cell lung cancer market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the non-small cell lung cancer market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to rising expenditure to develop healthcare infrastructure, rising prevalence of non-small cell lung cancer and rising geriatric population susceptible to cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The non-small cell lung cancer market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for non-small cell lung cancer market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the non-small cell lung cancer market. The data is available for historic period 2011-2021.
Competitive Landscape and Non-Small Cell Lung Cancer Market Share Analysis
The non-small cell lung cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to non-small cell lung cancer market.
Some of the major players operating in the non-small cell lung cancer market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- CLOVIS ONCOLOGY (U.S.)
- Johnson & Johnson Private Limited (U.S.)
SKU-